Ibrutinib
- Generic Name
- Ibrutinib
- Brand Names
- Imbruvica
- Drug Type
- Small Molecule
- Chemical Formula
- C25H24N6O2
- CAS Number
- 936563-96-1
- Unique Ingredient Identifier
- 1X70OSD4VX
- Background
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...
- Indication
Ibrutinib is indicated for the treatment of the following conditions.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Waldenström's macroglobulinemia
Chronic graft-versus-host disease (cGVHD)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)
- Associated Conditions
- Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
- Associated Therapies
- -
Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02272686
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT02271438
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
- Conditions
- Interventions
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT02268851
- Locations
- 🇺🇸
Pacific Cancer Care, Monterey, California, United States
🇺🇸St. Francis Hospital and Cancer Center, Hartford, Connecticut, United States
🇺🇸Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States
Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT02269085
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 229
- Registration Number
- NCT02264574
- Locations
- 🇬🇧
Site Reference ID/Investigator# 0867, Harlow, Essex, United Kingdom
🇦🇺Site Reference ID/Investigator# 0888, Ballarat, Victoria, Australia
🇦🇹Site Reference ID/Investigator# 0869, Salzburg, Austria
A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-09-29
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 85
- Registration Number
- NCT02251548
- Locations
- 🇺🇸
West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 37
- Registration Number
- NCT02242097
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Northwestern University- Lake Forest Hospital, Lake Forest, Illinois, United States
Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2023-11-28
- Target Recruit Count
- 156
- Registration Number
- NCT02232386
- Locations
- 🇮🇹
Unità di Onco-Ematologia - Azienda Ospedaliera - Garibaldi, Catania, Italy
🇮🇹UO Ematologia - AOU Policlinico di Modena, Modena, Italy
🇮🇹Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova, Reggio Emilia, Italy
Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT02219737
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 20
- Registration Number
- NCT02207062
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.